Investor Presentaiton

Adverse Events Safety population reporting treatment-emergent events AE and SAE rates were similar between treatment groups in both studies Rates of AESIs were generally similar between treatment groups in both studies asceND D DIALYSIS Daprodustat (N=1482) ESA (N=1474) asceND ND NON-DIALYSIS Rate of AEs Rate of SAES 88% 85% Rate of AES 52% 51% Rate of SAES Darbepoetin Daprodustat (N=1937) alfa (N=1933) 80% 77% 44% 36% Adverse Events of Special Interest (AESIs) undergoing further investigation: Esophageal and gastric 4.0% [60] 5.5% [81] erosions, % [n] Esophageal and gastric erosions, % [n] 3.6% [70] 2.1% [41] Cancer-related mortality and tumor progression and recurrence, % [n] 3.2% [47] 3.5% [51] Cancer-related mortality and tumor progression and recurrence, % [n] 3.7% [72] 2.5% [49] Safety population: all randomized patients who received at least one dose of randomized treatment. Treatment-emergent adverse events are reported which start or worsen on or after the participant's treatment start date and on or before the day after the participant's last dose of randomized treatment. Adverse events of special interest were investigator reported events and were not adjudicated. They were defined for da produstat based on data from non-clinical and clinical studies, current information about HIF-associated pathophysiology, and identified risks for ESAs. A programmatic approach for these potential events was implemented using a broad set of terms of interest. AE, adverse event; AESI, adverse event of special interest; ESA, erythropoiesis-stimulating agent; HIF, hypoxia-inducible factor; SAE, serious adverse event. 16

View entire presentation